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Phase II Study of the Histone Deacetylase Inhibitor
Romidepsin in Relapsed Small Cell Lung Cancer (Cancer
and Leukemia Group B 30304)
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and Everett E. Vokes‡; for the Cancer and Leukemia Group B
Introduction: Treatment of small cell lung cancer (SCLC) is
initially gratifying with most patients responding to platinum-based
chemotherapy. Treatment of relapsed disease gives much lower
response rates of short duration. We undertook this study of the
protein deacetylase inhibitor Romidepsin in chemosensitive recur-
rent SCLC based on preclinical data that suggested this to be an
active target.
Methods: Patients had recurrent chemosensitive SCLC (relapse
90 days since completion of platinum-based chemotherapy).
Treatment was administered as weekly infusions of Romidepsin at
13 mg/m2 for 3 of 4 weeks. We designed a two-stage phase II study
targeting a response rate of 30% (10% response would be unin-
teresting and 30% worthy of further study).
Results: Sixteen patients (10 male, 6 female) were accrued to the
first stage of this study. Most (11 patients, 69%) presented with
extensive-stage SCLC, and all had received prior chemotherapy,
with 11 having received prior radiation. Eastern Cooperative On-
cology Group performance status was excellent with 0 in 6 patients
(38%) and 1 in 10 patients. No objective responses were seen, and
stable disease was the best response seen in 3 patients (19%).
Toxicity was modest with 3 patients suffering grade 3 toxicity
(lymphopenia, insomnia, nausea, vomiting, and hyponatremia) and
one patient with grade 4 thrombocytopenia. Median progression-free
survival was 1.8 months, and median overall survival was 6 months.
Conclusion: Romidepsin given on a weekly schedule in patients
with chemosensitive, recurrent SCLC was inactive and will not be
pursued further in this setting.
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(J Thorac Oncol. 2010;5: 1644–1648)
Lung cancer is the leading cause of cancer-related death inthe United States. In 2009, it is estimated that there were
more than 219,000 new cases and 159,000 deaths.1 Small cell
lung cancer (SCLC) accounts for 15% of all lung cancer
and is clinically characterized by rapid growth, early meta-
static potential, and initial responsiveness to chemotherapy.
Treatment of SCLC is chemotherapy or radiation therapy or
both, depending on the stage.2 Despite often dramatic initial
responses to appropriate therapy, most patients with SCLC
relapse and die of treatment-resistant disease, resulting in an
overall 5-year survival rate of 10%.3 Treatment with plat-
inum-based chemotherapy plus thoracic radiotherapy has re-
sulted in impressive response rates of 80 to 90% in patients
with potentially curable limited-stage disease, but median
survival is only 15 to 21 months and 5-year survival is
20%.4 In patients with extensive-stage disease, platinum-
based chemotherapy also yields high initial response rates of
60 to 80%, but long-term survival is rare.5
Regardless of initial treatment, most patients will ulti-
mately relapse, and treatment with standard chemotherapy
approaches after initial treatment fails is of marginal benefit.
Salvage/second-line chemotherapy for SCLC has been disap-
pointing, and the single Food and Drug Administration-
approved drug, topotecan, results in transient response rates
of 6 to 37%, depending on the timing of relapse, with patients
relapsing within 90 days of initial treatment experiencing a
very poor response rate to any therapy. Patients with “sensi-
tive” relapse (90 days from completion of initial therapy)
have improved responses.6–8 One randomized study sup-
ported the use of topotecan in the second-line setting when
compared with combination therapy with cyclophosphamide,
doxorubicin, and vincristine in that there was equivalent
efficacy but less toxicity.9 Nonetheless, the time to progres-
sion in this study was 12 to 13 weeks. More recently, the
topoisomerase 2 inhibitor amrubicin seems to be an active
drug with impressive response rates in the first- and second-
line setting (both chemosensitive and chemorefractory dis-
ease).10–12 A first-line phase III study in China is currently
underway comparing amrubicin and cisplatin with etoposide
and cisplatin (NCT00660504), and a phase II study of amru-
bicin and carboplatin with pegfilgrastim support has been
initiated through the Sarah Cannon Research Institute
(NCT01076504). A variety of approaches including the use
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of pro-apoptotic molecules, retinoids, and novel cytotoxic
agents have been investigated in this setting.13–17
Romidepsin (FK 228, FR 901228) is a bicyclic peptide
originally isolated from Chromobacterium violaceum strain
968.18 Romidepsin is a potent inhibitor of the histone
deacetylase (HDAC) enzymes. Deregulation of histone acet-
ylation has been implicated in the development of several
types of cancer. Genes that encode enzymes that modify
histone acetylation are translocated, amplified, overex-
pressed, and/or mutated in various cancers.19,20 These find-
ings suggest that deregulated acetylation of histones plays a
role in the pathogenesis of hematological as well as solid
tumors by changing the chromatin structure and transcription
of genes involved in cell cycle control, differentiation, or
apoptosis.
Treatment of a number of lung cancer cell lines (in-
cluding SCLC cells) with HDAC inhibitors has led to alter-
ations in histone acetylation, decreases in cell viability, and
apoptosis.21 A phase I study by Sandor et al. tested a day 1,
day 5 schedule repeated every 21 days, and this was the initial
schedule for a phase II study of Romidepsin in Cutaneous
T-Cell Lymphoma by investigators at the National Cancer
Institute.22,23 Marshall et al.24 performed a phase I study of
Romidepsin in patients with advanced solid tumors and
lymphomas and found that the dose of 13.3 mg/m2 to be the
maximum tolerated dose when administered on a weekly
schedule for 3 of 4 weeks. The phase II study of Romidepsin
was amended to this schedule when it became clear that this
schedule and dose were more tolerable.23 Given the lack of
curative and even modestly effective treatment options for
patients with recurrent SCLC, and the interesting in vitro
data,21 we performed this phase II study of weekly Romidep-
sin in patients with chemosensitive, relapsed SCLC.
PATIENTS AND METHODS
Study Design and Objectives
This was a two-stage phase II trial with a primary end
point to evaluate the response rate of patients with histolog-
ically or cytologically proven SCLC treated with Romidepsin
in the “sensitive” relapse setting. The decision to study this
drug in the sensitive relapse setting was made after discussion
with Cancer Therapy Evaluation Program. Secondary objec-
tives included description of the overall and progression-free
survival of patients with chemosensitive, relapsed SCLC
when treated with Romidepsin on a weekly schedule. The
toxicity of Romidepsin in this population was another sec-
ondary end point. This trial was registered on clinicaltrials.
gov as NCT00086827.
Study Population
Patients were required to have histologically or cyto-
logically confirmed SCLC with disease that had progressed
after platinum-based therapy. They could not have had more
than one prior therapy and must have had “sensitive” disease
(progressing 90 days after completion of first-line ther-
apy).3,25 In addition, patients were required to have the
following characteristics: age older than 18 years, Eastern
Cooperative Oncology Group (ECOG) performance status 0
to 1, adequate bone marrow, hepatic, and renal function
(granulocytes 1500/L, platelets 100,000/L, total bili-
rubin 1.5  upper limit of normal [ULN], aspartate
transaminase 2.5  ULN, and creatinine 1.5  ULN [or
calculated creatinine clearance 60 ml/min]). Patients may
have received prior radiation but at least 4 weeks must have
elapsed since last treatment. Patients with significant cardiac
disease, who were HIV positive, or who required enzyme
inducing antiepileptic drugs were excluded. Each participant
signed an Institutional Review Board-approved, protocol-
specific informed consent in accordance with federal and
institutional guidelines.
Treatments
Romidepsin was administered at a dose of 13 mg/m2 as
a 4-hour infusion intravenously on days 1, 8, and 15 on a
4-week schedule. This dose and schedule were established by
a prior phase I study as tolerable in patients with advanced
solid tumors (T95-0022).24 For patients who achieved a
response (complete response or partial response) or stable
disease, therapy was continued for at least six cycles or two
cycles beyond their best response unless there was unaccept-
able toxicity. Prophylactic antiemetics (5-HT3 antagonists in
combination with steroids) were administered with each treat-
ment administration.
Dose Delays/Adjustments
Because of findings in an National Cancer Institute
phase I study, careful cardiovascular monitoring was re-
quired. Before each infusion, electrocardiogram with rhythm
strip was performed. If QTc was 500 milliseconds or there
was a prolongation of QTc (from baseline) of 33% or more,
treatment was held or discontinued unless a formal cardiol-
ogy consultation approved further treatment. If these abnor-
malities resolved, and cardiology “clearance” was obtained,
then treatment was allowed to be reinstituted at 10 mg/m2/wk.
Sinus tachycardia, atrial dysrhythmias, and changes in T
wave or ST segment morphology that resolved were similarly
evaluated and retreated (if resolved at 10 mg/m2/wk, and if
unresolved, no further treatment). Episodes of ventricular
arrhythmia or confirmed drop of left ventricular ejection
fraction (to 40%) was the reason to permanently discon-
tinue the study drug.
Metabolically, before each dose, treating physicians
were required to confirm that potassium was 4 mmol/L or
more and that serum magnesium was 0.85 mmol/L or more.
For patients who experienced hematologic toxicity dur-
ing a cycle (i.e., during weekly treatments) or at the begin-
ning of a subsequent cycle, treatment was delayed until
recovery of counts and then reinstituted at 10 mg/m2/wk.
Similarly, if patients experienced renal or hepatic toxicity,
treatment was delayed until resolution of toxicity and then
reinstituted at 10 mg/m2/wk. If, in any situation, treatment
was delayed for more than 3 weeks, treatment was discon-
tinued.
Response Assessment and Statistical Analysis
All patients meeting eligibility were included in anal-
ysis of response and survival. Kaplan-Meier curves were used
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to describe overall survival and progression-free survival.
Survival time was defined as the time between registration
and death, and progression-free survival was computed from
the time of registration to disease progression or death. All
patients who received any treatment were evaluable for tox-
icity, which was collected at the beginning of each cycle.
The primary end point/objective of this study was to
determine the objective response rate to Romidepsin at this
dose and schedule in patients with relapsed, chemosensitive
(defined as those who have relapsed 90 days after comple-
tion of primary/first-line therapy) SCLC. Response rate was
assessed via RECIST criteria with scans performed every two
cycles.26
A two-stage design that allowed for inexact sample
sizes within the first and second stage of the study was
adapted for this study. We considered a response rate of less
than 10% to be uninteresting and not worthy of further study
in this setting, whereas a response rate of 30% or more was
of interest for further study. Therefore, the statistical hypoth-
esis that was tested differentiated between a 10% and 30%
response rate: H0: p  0.1 versus H1: p  0.3, where p is the
proportion of patients who respond (complete or partial) to
the treatment.
Approximately 15 patients were to be entered into the
first stage of the study. If none of the patients responded to
treatment, the study was to be closed to further patient accrual
and the treatment regimen deemed as not being worthy of
further investigation. Otherwise, an additional 21 patients
(total 36) were to be accrued to the study. If 5 or fewer of the
patients responded to treatment, then the treatment regimen
would be rejected. Otherwise, the treatment regimen would
be considered worthy of additional investigation.
Assuming that 15, 16, or 17 patients were to be accrued
during the first stage of the study, and that a total of 36, 37,
or 38 patients were enrolled onto the study, the following
could be made about the characteristics of this study design:
Y The probability of concluding that the treatment regimen
is not worthy of further investigation (i.e., p  0.1)
when the true response rate is 30% is less than 0.075.
Y The probability of concluding that the treatment regimen
is worthy of further investigation (i.e., p 0.3) when the
true response rate is 10% is less than 0.075.
RESULTS
Sixteen patients were enrolled on this study over a
period of 12 months at Cancer and Leukemia Group B
institutions. Accrual was held until it was clear that the
primary end point was not achieved, and the study was then
permanently closed. Baseline demographic data and clinical
characteristics of the patients are shown in Table 1. The
median age was 69 years (range, 36–88 years), with more
men than women (62% compared with 38%). Nearly 69% of
the patients initially were treated with chemotherapy for
extensive-stage disease, with 31% of the patients receiving
prior therapy for limited-stage disease. Radiation therapy
(either definitive or palliative) had been delivered to 69% of
patients. Performance status was excellent (as defined by the
entry criteria) with most having ECOG of 1 (62%) with the
remaining being ECOG 0. Because this study was performed
in the chemosensitive disease setting, most patients had
previously responded well to initial therapy, with the best
response to prior therapy either complete response (25%),
partial response (31%), with 38% having stable disease.
Toxicity was generally mild with only three patients
suffering grade 3 toxicity (lymphopenia, insomnia, nausea, vom-
iting, and hyponatremia) and one patient with grade 4 toxicity
(thrombocytopenia). Table 2 details the serious toxicity seen in
this study. Before activation of the protocol, there was signifi-
cant concern about cardiac toxicity (prolonged QTc and arrhyth-
mias, atrial and ventricular); however, there were no grade 3 to
5 cardiac events noted in this study.
No patient had an objective response to treatment, with
the best “response” being stable disease in three patients
(19%). One patient was inevaluable for response data, and the
remainder (12–75%) had progressive disease. The patient
who was inevaluable for response withdrew consent on cycle
1, day 2 when notified of an IND safety report that had been
filed 1 week previously, describing a patient who experienced
sudden death. Therefore, the target response rate for the first
stage of the study was not met, and further accrual to the
second stage was halted. Median progression-free survival
was 1.82 months with 95% confidence interval of 1.54 to 3.52
months, and median overall survival was 5.96 months (95%
confidence interval 4.63–16.5). Figure 1 shows the Kaplan-
Meier curves of overall and progression-free survival.
TABLE 1. Patient Demographics
Characteristics N (%)
Age (yr)
Median 69
Range 36–88
Gender
Male 10 (62)
Female 6 (38)
Race
White 16 (100)
Staging at original diagnosis
Extensive SCLC 11 (69)
Limited SCLC 5 (31)
Previous chemotherapy
Yes 16 (100)
Previous radiation
Yes 11 (69)
No 5 (31)
Previous surgery
Yes 1 (6)
No 15 (94)
Performance status
0 6 (38)
1 10 (62)
Best response to prior chemotherapy/radiotherapy
Complete response 4 (25)
Partial response 5 (31)
Stable 6 (38)
Inevaluable 1 (6)
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DISCUSSION
Despite preclinical evidence of activity in vitro, Ro-
midepsin was disappointingly unable to positively impact the
disease in patients with recurrent SCLC.21 Since this study
was initiated, Vorinostat, another HDAC inhibitor, and Ro-
midepsin have both been approved for the treatment of
cutaneous T-cell lymphoma.23,27 The strategy of histone/
protein deacetylase inhibition is undergoing intensive study
in a number of other liquid and solid tumors including
thoracic malignancies.27
At least three potential explanations can be envisioned
for the failure of this drug to work in this setting. First, it may
be that recurrent SCLC is the wrong disease to study. Clearly,
recurrent SCLC is a difficult and refractory disease (even in
the “chemosensitive” setting) with only a single agent (topo-
tecan) receiving Food and Drug Administration approval for
treatment in this setting. Unfortunately, other than data that
has been generated from cell lines, little is known about the
molecular events that characterize relapsed SCLC.5 One of
the challenges has been the relative inability to procure
sequential tumor biopsy samples to interrogate via modern
molecular techniques. The relative lack of understanding of
mechanisms of resistance is particularly true in the relapsed
setting when rebiopsy is often not performed because of the
perceived (and real) urgent need for subsequent treatment.
The second possibility is that Romidepsin is the wrong
protein deacetylase inhibitor. Although Romidepsin is quite
potent in vitro, with IC50s in the nanomolar range, it is
possible that the other protein deacetylase inhibitors (Vori-
nostat or others) have better in vivo activity in patients with
disease. Unfortunately, the initial results of Vorinostat and
other HDAC inhibitors in non-lymphoma or leukemia set-
tings are distinctly disappointing.
Finally, it is possible that single-agent activity of this
drug (or class of drugs) in the setting of common epithelial
tumors (as opposed to lymphoid malignancies such as adult
T-cell leukemia/lymphoma) is inadequate and that in order
for this type of agent to make a difference, we will need to
combine it (or others of this class) with other agents such as
cytotoxic chemotherapy or potentially radiation therapy.28,29
This also raises the interesting possibility that the effect of the
so-called HDAC inhibitors is not solely on histone post-
translational modifications but potentially on the acetylation
of other proteins important for cellular homeostasis such as
tubulin, p53, and others. In lung cancer (both small cell and
FIGURE 1. A, Kaplan-Meier curve for overall survival (median 6 months). B, Kaplan-Meier curve for progression-free survival
(median 1.8 months).
TABLE 2. Adverse Events
Grade of Adverse Event
3  Severe
4  Life
Threatening
Hematologic adverse events
Blood/bone marrow
Lymphopenia 1 (6)
Platelets 1 (6)
Maximum hematologic adverse
events
1 (6) 1 (6)
Nonhematologic adverse events
Constitutional symptoms
Insomnia 1 (6)
Gastrointestinal
Nausea 1 (6)
Vomiting 1 (6)
Metabolic/laboratory
Hyponatremia 1 (6)
Maximum nonhematologic
adverse events
3 (19)
Maximum overall adverse events 3 (19) 1 (6)
Values are given as n (%).
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non-small cell cancer), the strategy of HDAC inhibitors as
single agents have given way to incorporate these agents
(Romidepsin, Vorinostat, and others) in combination
with cytotoxic chemotherapy (for example NCT00702962),
novel molecular targeted agents (NCT00503971 and
NCT00098644), or radiation therapy (for example
NCT00662311). Unfortunately, despite initial promise in a
randomized phase II study,30 the phase III trial comparing
chemotherapy with or without Vorinostat was recently termi-
nated based on the recommendation of the Data Safety
Monitoring Board from a preplanned interim analysis that the
study failed to achieve its end point (NCT00473889). Other,
ongoing trials emphasize the role of biomarker development
and validation for HDACs as a target.
Moving forward, it is clear that a better understanding
of the molecular events (and hopefully targetable events) that
lead to recurrent/progressive SCLC will be required.
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